Jennifer Woyach, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, speaks about the BRUIN CLL-322 study.
The phase III open-label randomized study will evaluate fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.
It is currently enrolling patients who have previously received a Bruton’s tyrosine kinase inhibitor.
“I think it’s a really excellent trial,” Dr. Woyach said.
Dr. Woyach and colleagues presented information about the study’s design and enrollment process during the 2023 American Society of Clinical Oncology Meeting.